Novo Nordisk

Pharmaceuticals, health care

Based in DC

🤖

AI Overview

With $420K in lobbying spend across 10 quarterly filings, Novo Nordisk is an active lobbying client. Their lobbying covers 5 issue areas. Active from 2018 to 2019.

$420K
Total Spend
2
Years Active
1
Firms Hired
4
Lobbyists Deployed
5
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2018$160K
2019$260K

Issues Lobbied

Lobbying Firms

Lobbyists

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Budget/Appropriations, Taxation, Pharmacy, Medicare/Medicaid, Health Issues

  • - Preventative Health Savings Act (H.R. 2953/S. 216); CBO scoring of preventive health, generally
  • - National Diabetes Prevention Program and other CDC diabetes prevention activities in Pub.L. 115-96 (
  • - Implementation of the Tax Cuts and Jobs Act (Pub.L. 115-97)
  • - Issues related to the 340B Drug Pricing Program, generally; 340B Protecting Access for the Underserved and Safety-Net Entities (340 PAUSE) Act (H.R. 4710)
  • - Issues related to the FDA Reauthorization
  • - Treat and Reduce Obesity Act (H.R. 1953/S. 830)
  • - Medicare Diabetes Prevention Program; diabetes self-management education
  • - Issues related to Medicare Part D included in the Bipartisan Budget Act
  • - Diabetes prevention, generally
  • - Implementation of the Clinical Care Commission Act (Pub.L. 115-80)
  • - World Hemophilia Day
  • - Issues related to medication affordability and access, generally
  • - Americ

Related Analysis

Related Investigations

Similar Clients

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.